Anzeige
Mehr »
Sonntag, 10.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4114D | ISIN: US3622AW4030 | Ticker-Symbol:
NASDAQ
08.08.25 | 19:21
1,240 US-Dollar
-0,80 % -0,010
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GRI BIO INC Chart 1 Jahr
5-Tage-Chart
GRI BIO INC 5-Tage-Chart

Aktuelle News zur GRI BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
GRI BIO Aktie jetzt für 0€ handeln
31.07.GRI Bio, Inc.: GRI Bio CEO, Marc Hertz, Participates in Virtual Investor "What This Means" Segment1
31.07.GRI Bio: Positive Biomarker-Daten in Studie zur Behandlung von Lungenfibrose4
31.07.GRI Bio reports positive interim biomarker results in IPF treatment study1
31.07.GRI Bio, Inc.: GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF")108Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response The Independent Data Monitoring Committee (IDMC) has recommended...
► Artikel lesen
31.07.GRI Bio, Inc. - 8-K, Current Report-
02.07.GRI Bio-Aktie behält Kaufempfehlung von H.C. Wainwright nach Abschluss der Phase-2a-Studie1
02.07.GRI Bio stock holds Buy rating at H.C. Wainwright as Phase 2a trial completes enrollment2
01.07.GRI Bio, Inc.: GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis ("IPF")270Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival 2- and 6-week interim safety...
► Artikel lesen
26.06.GRI Bio meldet positive Sicherheitsdaten für IPF-Behandlungskandidat2
26.06.GRI Bio, Inc.: GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF")175The Independent Data Monitoring Committee ("IDMC") has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed Interim results to date demonstrate...
► Artikel lesen
26.06.GRI Bio, Inc. - 8-K, Current Report2
11.06.H.C. Wainwright REITERATES Buy rating on GRI Bio stock2
23.05.GRI Bio erweitert Kapazität für At-the-Market-Angebot2
23.05.GRI Bio, Inc. - 8-K, Current Report1
22.05.GRI Bio reports progress in pulmonary fibrosis treatment1
22.05.GRI Bio verzeichnet Fortschritte bei Behandlung von Lungenfibrose2
22.05.GRI Bio, Inc.: GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results2
21.05.GRI Bio, Inc.: GRI Bio to Participate in the Virtual Investor Closing Bell Series1
16.05.GRI Bio, Inc.: GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase5
15.05.GRI Bio reports Q1 results2
Weiter >>
59 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1